TBPH Theravance Biopharma, Inc.

33.78
+1.38  (4.26%)
Previous Close 32.40
Open 32.40
Price To book 5.23
Market Cap 1.75B
Shares 51,942,000
Volume 272,735
Short Ratio 19.05
Av. Daily Volume 284,926

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due mid-2017.
TD-9855
nOH
Phase 3 study completion due 2018.
Closed Triple
Asthma
NDA filing submission announced November 21, 2016.
Closed Triple
COPD
Phase 3 trials met primary endpoint. 12 month safety trial data (mid-2017) and NDA filing end of 2017.
Revefenacin
COPD
Phase 2b initiated mid March 2015. Data due mid-2017.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 data due 2018
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD

Latest News

  1. 8:31 am Theravance Biopharma Presents Positive Clinical Data on TD-1473
  2. Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  3. Theravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017
  4. Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  5. Theravance Biopharma to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  6. Theravance's Infection Drug Vibativ Positive in TOUR Study
  7. Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : January 23, 2017
  8. Theravance Biopharma Reports New Data from Ongoing TOUR™ Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress
  9. Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : January 20, 2017
  10. Theravance Biopharma to Present New Data from Ongoing TOUR™ Observational Patient Registry at SCCM Critical Care Congress
  11. THERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  12. The Zacks Analyst Blog Highlights: ELEMENTS SPECTRUM Large Cap U.S. Sector Momentum Index ETN, Advanced Micro Devices, AK Steel Holdings, Theravance Biopharma and Fairmount Santrol Holdings
  13. Coverage initiated on Theravance Biopharma by Needham
  14. Theravance Biopharma Highlights Initiation of Phase 3 Study of the Closed Triple in Patients with Asthma by GlaxoSmithKline and Innoviva
  15. Favorite Healthcare Stocks of Billionaire Seth Klarman’s Baupost Group
  16. Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : December 12, 2016
  17. Michael Burry: Current Holdings and a Change of Style
  18. Is Theravance Biopharma Inc (TBPH) A Good Stock To Buy?
  19. Theravance Stock Up on Fast Track Status for Velusetrag
  20. Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
  21. Theravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva
  22. Theravance Biopharma to Present at the 28th Annual Piper Jaffray Healthcare Conference
  23. Theravance Biopharma, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update
  24. Theravance Biopharma to Report Third Quarter 2016 Financial Results on November 8, 2016
  25. New Data for VIBATIV® (telavancin) Reported in Presentations at IDWeek™ 2016
  26. Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR™) at IDWeek™ 2016
  27. Theravance Biopharma Announces Pricing of Public Offerings of 3,850,000 Ordinary Shares and $200 Million of 3.25% Convertible Senior Notes due 2023
  28. Theravance Biopharma Announces Proposed Public Offerings of $100 Million of Ordinary Shares and $150 Million of Convertible Senior Notes
  29. Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP)
  30. Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
  31. Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV(R) (telavancin), Including Ongoing TOUR(TM) Observational Patient Registry, at IDWeek 2016
  32. Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis
  33. Theravance Biopharma, Inc. Reports Second Quarter 2016 Financial Results and Provides Business Update
  34. Theravance Biopharma to Report Second Quarter 2016 Financial Results on August 8, 2016
  35. Theravance Biopharma to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
  36. Theravance Biopharma Announces New Employment Inducement Awards
  37. Theravance Biopharma to Present New Data Highlighting Potent in vitro Activity of VIBATIV(R) (telavancin) Against Difficult-to-Treat, Clinical Pathogens, Including MRSA, at ASM Microbe 2016 Conference
  38. Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor
  39. Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
  40. Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
  41. Theravance Biopharma Announces New Employment Inducement Awards
  42. Theravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva